A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa (NCT07384975)
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
🩺 Plain-English Summary (8th-Grade Level)
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study). Participants will: * Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.
Who can join: Review the eligibility criteria below.
Location: Medical Dermatology Specialist — Phoenix, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- Medical Dermatology Specialist — Phoenix, Arizona
- Scottsdale Clinical Trials — Scottsdale, Arizona
- Accel Research Sites Network — Maitland, Florida
- Floridian Research Institute — Miami, Florida
- Cordova Research Institute — Miami, Florida
- Ziaderm Research, LLC — North Miami Beach, Florida
- FWD Clinical Research — Tamarac, Florida
- MplusM - D&H Tamarac Research Center — Tamarac, Florida
- ForCare Clinical Research — Tampa, Florida
- Kentucky Advanced Medical Research LLC — Murray, Kentucky
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- SKY Integrative Medical Center — Ridgeland, Mississippi
- StracSkin, PLLC — Portsmouth, New Hampshire
- Equity Medical, LLC — The Bronx, New York
- Medical Center Medconsult Pleven — Lovech,
- MC Medconsult Pleven — Pleven,
- Ambulatory for Specialized Medical Help - skin and venereal diseases — Sofia,
- Diagnostic Consultative Center Fokus-5 Medical Establishment for Outpatient Care EOOD — Sofia,
- FACET Dermatology — Toronto, Ontario
- Research Toronto — Toronto, Ontario
- Centre de Recherche Saint-Louis (Quebec) — Montreal, Quebec
- LTD Aversi Clinic - Dermatology — Tbilisi,
- LTD Israel-Georgian Medical Research Clinic Healthycore — Tbilisi,
- LTD MediClub Georgia — Tbilisi,
- LTD Multiprofile Clinic Consilium Medulla — Tbilisi,
📞 Contact the Study Coordinator
Phone: (415) 251-7753
Email: info@navigatormeds.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hidradenitis Suppurativa (HS)
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense — Phoenix, Arizona
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
- Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa — Missouri City, Texas
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) — Irvine, California
- A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa — Worcester, Massachusetts
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa — Chapel Hill, North Carolina
Explore by condition: All Hidradenitis Suppurativa (HS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.